Keenova Therapeutics plc Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Keenova Therapeutics plc reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of -$25.00 million for the 9-month period ending 2017-09-29, per its 10-Q filed 2017-11-07.
Discontinued › Notes › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2017-11-07
- Keenova Therapeutics plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-09-29 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month |
|---|---|---|---|
| 2017-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$25.00M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$25.00M 10-Q · filed 2017-08-08 |